Fundz

Who to call at Innovent Biologics, and when

Fundz watches for the moments Innovent Biologics starts buying, and tells you who to reach.

  • An alert the day Innovent Biologics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Innovent Biologics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Innovent Biologics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Innovent Enters Exclusive License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate

Jan 02, 2025

Contract Type

agreement

SuzhouManufacturingBiotechnologyHealth CarePharmaceuticalPharmaceutical Manufacturing

Description

Innovent Biologics, Inc. has announced an exclusive license agreement and collaboration with Roche to advance the development of IBI3009, a novel DLL3-targeted antibody drug conjugate (ADC) candidate aimed at bringing innovative treatment options to patients with advanced small cell lung cancer.

Company Information

Company

Innovent Biologics

Location

Suzhou, Jiangsu, China

About

Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of major diseases such as cancer. On 31 October, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK. Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection), SULINNO® (adalimumab injection), HALPRYZA® (rituximab injection) officially approved for marketing in China, 5 assets in Phase III or pivotal clinical trials, and additional 14 molecules in to clinical trials. TYVYT® was included in the National Reimbursement Drug List (NRDL) in 2019 as the only PD-1 in that year and was also the first PD-1 inhibitor included in NRDL historically.

Related People

Fei
Likely contact at this company
••••••••@••••••••

See Fei's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Innovent Biologics's next move

Learn about Strategic plan

Innovent Biologics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.